Genentech’s 340B Discounts Making Their Mark On Product Pricing

Genentech’s 340B drugs discounts totaled $1 billion in 2012 and are growing at 20% to 25% a year, a level that has prompted management to sit up and take notice, including setting up a team to work with 340B health care providers on compliance.

More from United States

More from North America